Matthew Wall
Neuroscientist
Papers
Trials
Key Impact
Noted for advancing neuroimaging characterisation of how classic and entactogenic psychedelics (psilocybin, LSD, MDMA) alter large-scale brain networks and emotional processing, informing clinical development.
Background & Research
Matthew Wall is a neuroimaging scientist based at Imperial College London who specialises in functional MRI studies of psychoactive compounds and their effects on human brain function. He has collaborated with leading psychedelic research groups and clinical teams to image acute and short-term brain changes after administration of psilocybin, LSD and MDMA, and has acted as principal imaging scientist on early fMRI investigations of psilocybin in treatment-resistant depression. His methodological work spans task-evoked and resting-state paradigms and includes studies linking musical and emotional processing to drug-induced changes in brain activity.
Wall's contributions include empirical studies of LSD- and MDMA-related modulation of striato‑cortical connectivity, investigations of music‑evoked brain responses under LSD, analyses of first‑use psilocybin brain changes, and naturalistic work on MDMA/ecstasy and social behaviour. He is a co-author of recent reviews charting the role of neuroimaging in psychedelic drug development and has helped to integrate network‑level and affective neuroscience perspectives into translational research on psychedelic-assisted therapies.